Article Listing - Synthelabo R&D focus on CNS, cardiovascular and internal medicine

APPOINTMENTS AT XOMA CORP

4 May 1992

US biotechnology company Xoma Corporation has announced the appointment of John Castello as president and chief executive officer. Mr Castello...

APPOINTMENTS AT BAYER

4 May 1992

Mannfred Schneider has been named as president of Bayer AG of Germany, in succession to Hermann Strenger. Dr Schneid-er is...

IDEC PHARMA'S RICHARD KRAWIEC

4 May 1992

Richard Krawiec has been appointed as director of investor relations and corporate communications at IDEC Pharmaceutical Corporation.

PFIZER RESEARCH SPENDING IN 1992

4 May 1992

US pharmaceutical manufacturer Pfizer said that it intends to spend $866 million on research and development in the current year,...

ROMANIAN HEALTH BUDGET STRIKE

4 May 1992

In Romania, the federation of medical workers' unions, the FSIMR, has threatened to call health service workers out on strike...

BEHRINGWERKE SALES JUMP 15.8%

4 May 1992

The German biological and diagnostic products-manufacturing subsidiary of Hoechst, Behringwerke, saw worldwide sales increase by 15.8% to 1.93 billion Deutschemarks...

ROUSSEL JAPAN CASH INJECTION

4 May 1992

A formal merger between the Roussel-Uclaf and Ajinomoto subsidiary companies on the Japanese drug market has now been signed, creating...

EMIP STUDY BACKS EARLY USE OF EMINASE

4 May 1992

Reporting from the annual meeting of the American College of Cardiology in Dallas, USA, the chief coordinator of the European...

COMPANIES DO MORE LICENSING DEALS

4 May 1992

There has been an increase in out-licensing of late-stage development drugs or mature drug product lines from research-intensive established drug...

US FDA APPROVABLE LETTER TO PFIZER

4 May 1992

The US Food and Drug Administr-ation has issued an "approvable" letter for Norvasc (amlodipine), a calcium channel blocker for the...

Showing 94311-94320 of 95572 articles